logo  
Sign in or Register

Already a member?

Sign in

Or sign in with your account on:

Not a member yet?

Register
    

IPO Report: Intrexon (XON)

By  +Follow August 7, 2013 11:03AM
Share:
Tickers Mentioned:

Nine other IPOs were scheduled for the week of August 5. The full IPO calendar can be found at IPOpremium.

Intrexon ($XON) is based in Germantown, MD.  XON scheduled a $124 million IPO with a market capitalization of $1.4 billion at a price range mid-point of $15, for Thursday, August 8, 2013.

The price range was set in theS-1 filed July 29, 2013.  The manager and joint manager are J.P. Morgan & Barclays.  The co-managers are Griffin Securities & Mizuho Securities

Summary

XON believes it is a leader in the field of synthetic biology, an emerging and rapidly evolving discipline that applies engineering principles to biological systems.

Q1 '13 $4 million in revenue with a $36 million loss.

One person owns 71%, apparently no venture capitalists, and no collaborators are investors. No patents, yet.

XON is bringing its technology to the market through collaborations, of which there are currently nine. Two are private companies and seven are public. The only large collaborator is Elanco, the animal health division of Eli Lilly and Company (LLY) , $57 billion market capitalization.

The rest are mostly micro cap companies, two of which have contributed stock to XON in return for the technology.

XON has an accumulated deficit of $363 million, and has raised $559 million to-date. Not entirely clear where that $559 million came from.

Valuation

Valuation Ratios

IPO Mrkt

Price /

Price /

Price /

Price /

% offered

annualizing Q1 '13

Cap (mm)

Sls

Erngs

BkVlue

TanBV

in IPO

Intrexon ($XON)

$1,410

88.1

-9.8

4.3

5.2

9%

Glossary

Only 9% is being offered on the IPO, a surprisingly small amount for a company that lost $36 million in Q1 '13. XON is IPO'ing at 4.3 times book, which seems reasonable

Conclusion

The rating is buy because if the technology is for real then XON could be a big stock. $559 million has been invested in the past several years, which is an indication some investors have done their due diligence, and 4.3 times book value is in range for this kind of company.

To put the conclusions and observations in context, the following is reorganized, edited, and summarized from the full S-1 referenced above:

Business

XON believes it is a leader in the field of synthetic biology, an emerging and rapidly evolving discipline that applies engineering principles to biological systems.

Synthetic biology aims to engineer gene-based programs or codes to modify cellular function to achieve a desired biological outcome. For example, applications may include the replacement of a defective protein with a functional protein to treat a broad range of human and animal disease states, or the production of multiple proteins through the regulation of several genes in a cell to produce petrochemicals.
Wikipedia.

Using proprietary and complementary technologies, XON designs, builds and regulates gene programs, which are DNA sequences that consist of key genetic components.

A single gene program or a complex, multi-genic program are fabricated and stored within a DNA vector. Vectors are segments of DNA used as a vehicle to transmit genetic information.

DNA vectors can, in turn, be introduced into cells in order to generate a simple or complex cellular system, which are the basic and complex cellular activities that take place within a cell and the interaction of those systems in the greater cellular environment.

It is these genetically modified cell systems that can be used to produce proteins, produce small molecules, or serve as cell-based products, which enable the development of new and improved products and manufacturing processes across a variety of end markets, including healthcare, food, energy and environmental sciences.

Intrexon's synthetic biology capabilities include the ability to precisely control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale.

Exclusive Channel Collaborations (ECCs)

XON provides expertise in the engineering, creation and modification of gene programs and cellular systems, and collaborators are responsible for providing market and product development expertise, as well as regulatory, sales and marketing capabilities.

Generally, the collaborators compensate XON through payment of technology access fees, royalties, milestones and reimbursement of certain costs.

Nine ECC agreements

XON began entering into ECCs in 2011 and are currently party to nine such agreements.

Under these ECCs, XON is developing products in the fields of healthcare and food. In healthcare, ECCs include programs in oncology, anti-infectives, antibiotics and tissue repair.

In food, XON is working to increase the productivity and nutritional value of salmon and other fish. XON is are also working to establish ECCs in the areas of energy and environmental sciences.

Seven ECC companies are public

Except for Elanco (Eli Lilly division) the companies are all micro caps. The largest market cap is ZIOP, with a market cap of $249 million.

If the technology is to be worth $1.4 billion XON's IPO, then XON should have larger, better known collaborators receiving exclusives.

ZIOPHARM Oncology

Effective January 6, 2011, XON entered into an ECC with ZIOPHARM Oncology, Inc. (ZIOP) , or ZIOPHARM, $249 million market capitalization.

Elanco

Effective November 28, 2011, XON entered into an ECC with Elanco, the animal health division of Eli Lilly and Company (LLY) , $57 billion market capitalization.

Fibrocell

Effective October 5, 2012, we entered into an ECC with Fibrocell Science, Inc. (FCSC) , $130 market capitalization.

Oragenics

Effective June 5, 2012, XON entered into an ECC with Oragenics, Inc. (OGEN) , $86 million market capitalization.

Synthetic Biologics

Effective August 6, 2012, XON entered into an ECC with Synthetic Biologics, Inc. (SYN) , $68 million market cap.

AquaBounty

AquaBounty Technologies, Inc. ($ABTX), $45 million market cap. XON also owns 54% of ABTX, as of Mach 15, 2013.

AmpliPhi

Effective March 29, 2013, XON entered into an ECC with AmpliPhi BioSciences Corp. (APHB) , $11 million market cap. XON received 24 million shares as an upfront access fee.

Soligenix

Effective April 27, 2013, XON entered into an ECC with Soligenix, Inc. ($SNGX), $20 million market cap. XON received 1 million shares as an upfront technology access fee.

XON also entered into agreements with two private companies

Markets

Synthetic biology has applicability across many diverse end markets.

Healthcare

  Therapeutics. Both in human health and animal health, synthetic biology has the potential to enable the development of highly complex biological molecules as well as the ability to regulate complex biological processes, with advantages as compared to traditional therapeutics, both in vivo and ex vivo. It may be possible, for example, to create highly targeted precision therapeutics with few off-target or adverse effects.

  Bioproduction Synthetic biology allows new biologically based manufacturing techniques that have the potential to significantly lower the cost of goods for highly complex biological molecules, including both existing and novel biopharmaceuticals as well as small molecules.

  Diagnostics By utilizing the sensing and reporting capabilities of cells and specific cellular mechanisms, it may be possible to create highly sensitive diagnostics, to report on a patient's health and provide advance warning of changes in the state of the patient's health.

Food

  Food animals By applying its suite of technologies, XON believes it can more rapidly develop livestock with commercially valuable attributes such as enhanced nutritional content, resistance to disease and increased growth efficiency.

  Agriculture XON believes that it can use gene expression and gene regulation technologies to provide highly complex traits related to enhanced nutritional content, product quality and disease resistance.

Energy and chemicals

  Energy XON has already achieved as proof of concept the conversion by engineered bacteria of methane to isobutanol, which is an alternative alcohol-based fuel.

  Chemicals Economically viable alternatives to carbon feed stocks are critical to the future and sustainability of the chemical industry.

Environmental sciences

  Biosensors The biosensor global market is forecasted to exceed $12 billion by 2016 and opportunities exist to capture a portion of this market through design and construction of unique biosensors that leverage XON's suite of proprietary and complementary technologies.

  Bioremediation The global market for microbial and associated bioremediation products is forecasted to reach over $1 billion by 2016. Industrial sources of soil and groundwater contamination present major environmental, policy and health issues because of the adverse effects of contaminants on humans and ecosystems. Bioremediation, which XON believes its technologies have the potential to enable, can provide an environmentally friendly, socially acceptable, effective and economically viable solution.

  Specialty Processes XON believes its suite of proprietary and complementary technologies has the potential to be used to introduce effective solutions for applications such as activated microbial filtration, waterborne pathogen elimination, and de-nitrification of waste and surface water.

XON's approch

The essence of XON's approach is to apply synthetic biology by using an iterative process that is rapid, automated and highly reproducible, in which we:

Design genes of interest and gene programs utilizing knowledge of cellular pathways and protein function;

Build biological molecules, gene programs and their variants to optimize performance of the biological system;

Test gene programs by inserting them into cellular systems and comparing the result(s) to the intended effects; and

Learn by utilizing information gained in our iterative processes to create better DNA vectors and gene programs using a more informed and efficient process to achieve improved outcomes.

As a result of its approach, XON has developed extensive knowledge about many classes of DNA components and the rules governing their expression and activity. XON has also assembled an inventory of these DNA components that XON can use to rationally construct unique vectors rapidly and with predictable outcomes. The knowledge embedded in XON's DNA database allows XON to create single gene and highly complex multigenic gene programs (an individual gene program containing multiple genes).

Integrated technologies

To support the design-build-test-learn approach, XON developed a unique suite of technologies. These technologies are complementary in nature and share the following key characteristics:

Platform neutral - outcome oriented.

Knowledge driven.

Rationally designed. XON's knowledge of biological systems and components allows XON to design, build and select gene programs and predict the probable outcome of these programs.

Capable of complexity. XON's technologies enable the design and precise control of complex biological molecules and multigenic gene programs.

Industrial scale. XON uses engineering principles and automation to enable products based on synthetic biology that are commercially viable.

Intellectual property

XON seeks patent protection for its platform technologies.

Competition

XON does not believe that it has any direct competitors who provide similar technologies which fully enable the commercialization of products developed using synthetic biology across a broad spectrum of biologically based industries. As a result, XON believes its competition is more indirect and general in nature, and falls into three broad categories:

• Synthetic biology service providers
There are companies that have competing technologies for individual pieces of XONs suite of complementary technologies. XON believes the following companies engage in the manufacture of DNA componentry: DNA 2.0, Inc., Blue Heron Biotech, LLC and Life Technologies Corporation. Another portion of our proprietary technology includes development of fully human monoclonal antibodies.

XON's technology utilizes advanced methods of stimulating antibody production in naïve human B-cells in vitro and specifically selecting those cells which produce antibodies that can bind a desired target, such as human toxins, tumor cells or microbial pathogens.

XON believes the following companies engage in the manufacture of human or human-like monoclonal antibodies: AbD SeroTec (a Bio-Rad Laboratories, Inc. company), Alexion Pharmaceuticals, Inc., XOMA Corporation, Genmab US, Inc., MorphoSys AG, NovImmune SA, Société Des Systèmes Biologiques, or BIOTEM, Adimab, LLC, ProMab Biotechnologies, Inc., Abpro, Inc., AIIM Therapeutics and Open Monoclonal Technology, Inc.

• Industrial companies who may develop their own approach to synthetic biology. Large biopharmaceutical companies, energy companies, and ag-bio companies may pursue a proprietary synthetic biology strategy.

• Industrial companies who may develop competing products using other technologies. Large biopharmaceutical companies pursue other technologies for drug development, and large ag-bio companies pursue other technologies for the development of genetically modified crops.

5% stockholder pre-IPO

Randal J. Kirk, 71%

Use of proceeds

XON expects to net $113.5 million from its IPO.

Proceeds are allocated to further business development efforts to consummate new collaboration agreements with new companies across various commercial divisions, and for working capital and other general corporate purposes.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions.


Liked What You Read? Join Equities.com as a contributor and get eyeballs on your content FOR FREE!

Results for XON
biotech 2050
25 Oct 14 21:35:53
RT @Melikeitalot: $ZIOP $XON If you ask some of the so-called experts who know nothing about either company of course they will give you no…
biotech 2050
25 Oct 14 21:34:09
RT @BowersMarty: @bradloncar @Biotech2050 @BioTerp You're partially right. Think they will prove w $xon to possess significant next buildin…
HotKeyTrading
25 Oct 14 20:30:08
Price Declines: $UPL $MIC $HNT $ABAX $SB $FTK $CCIH $AAN $ELS $STE $HTLD $WCC $MINI $EQM $XON http://t.co/Vv2VEn80mr #swingtrading #stock
Me Likeitalot
25 Oct 14 17:20:26
$ZIOP $XON If you ask some of the so-called experts who know nothing about either company of course they will give you non sensible answers.
MFB
25 Oct 14 15:59:44
@bradloncar @Biotech2050 @BioTerp You're partially right. Think they will prove w $xon to possess significant next building block in CAR T
HotKeyTrading
25 Oct 14 08:30:13
Price Declines: $UPL $MIC $HNT $ABAX $SB $FTK $CCIH $AAN $ELS $STE $HTLD $WCC $MINI $EQM $XON http://t.co/XQITF0lRKD #spy #trader #mkt #dow
wininstocks2014
24 Oct 14 22:08:22
XON 20.45 Stock Charts $XON Intrexon Corp. (NYSE) Last Updated: 10/25/2014 00:08:21 XON Stock Chart - 1 Month http://t.co/4SJJxvBYnb
HotKeyTrading
24 Oct 14 20:30:19
Price Declines: $ABAX $SB $FTK $CCIH $AAN $ELS $STE $HTLD $WCC $MINI $EQM $XON $SRCL $GPI $UFS http://t.co/Vv2VEn80mr #trader #watchlist
4-traders.com
24 Oct 14 13:45:04
INTREXON : Financial Statements and Exhibits (form 8-K/A) http://t.co/ycY5TwBfi5 $XON
NASDAQ
24 Oct 14 13:40:13
$XON - Amended Current Report Filing (8-k/a) http://t.co/nnksV75671
biotech 2050
24 Oct 14 13:18:34
RT @pharmamaven: @OptionsHawk Kirk will definitely get a $ZIOP deal done by yr end imo with Big Pharma in this hot space. $XON technology w…
Me Likeitalot
24 Oct 14 13:00:55
RT @pharmamaven: @OptionsHawk Kirk will definitely get a $ZIOP deal done by yr end imo with Big Pharma in this hot space. $XON technology w…
809trader
24 Oct 14 12:56:53
RT @pharmamaven: @OptionsHawk Kirk will definitely get a $ZIOP deal done by yr end imo with Big Pharma in this hot space. $XON technology w…
rc
24 Oct 14 12:56:13
@OptionsHawk Kirk will definitely get a $ZIOP deal done by yr end imo with Big Pharma in this hot space. $XON technology will be validated.
Large Void Bot
24 Oct 14 12:00:21
Popular: $INVN, $F, $RGLS, $ARIA, $CCIH, $ATVI, $REXX, $M, $WDAY, $XON, $BREW, $NTAP
biotech 2050
24 Oct 14 11:30:41
RT @pharmamaven: Kirk $XON been negotiating a $ZIOP deal for a yr-HUGE option vol & stock hi vol 50DMA breakout=deal near. Smart shorts cov…
rc
24 Oct 14 10:45:33
Kirk $XON been negotiating a $ZIOP deal for a yr-HUGE option vol & stock hi vol 50DMA breakout=deal near. Smart shorts cover before weekend
Alexander Morris
24 Oct 14 10:32:29
$XON: Exc 1MoHIGH=20.69, hits:4, Rng:22%, ch:+0.5%[1.2%offHi], PrvCHi+, FltBO+, tf:1111100, LowFlt[16.5M], HiPctSht[71%:18d]
biotech 2050
24 Oct 14 10:04:59
RT @pharmamaven: Insane short interest in tightly held $ZIOP with $XON Kirk's history could cause HUGE run on deal PR...& then reval http:/…
biotech 2050
24 Oct 14 09:40:30
RT @pharmamaven: Hi volume multi day $ZIOP breakout on 2k, 2k, 9k, 4k+ call volume breaking 50 DMA/EMA like hot knife through butter is VER…
809trader
24 Oct 14 09:28:45
RT @pharmamaven: Insane short interest in tightly held $ZIOP with $XON Kirk's history could cause HUGE run on deal PR...& then reval http:/…
Colony Records
24 Oct 14 08:58:59
RT @pharmamaven: Insane short interest in tightly held $ZIOP with $XON Kirk's history could cause HUGE run on deal PR...& then reval http:/…
Offshorehunter
24 Oct 14 08:58:58
$XON hod, off last nights list
Colony Records
24 Oct 14 08:58:44
RT @pharmamaven: Hi volume multi day $ZIOP breakout on 2k, 2k, 9k, 4k+ call volume breaking 50 DMA/EMA like hot knife through butter is VER…
rc
24 Oct 14 08:57:34
Hi volume multi day $ZIOP breakout on 2k, 2k, 9k, 4k+ call volume breaking 50 DMA/EMA like hot knife through butter is VERY important. $XON
rc
24 Oct 14 08:54:45
Insane short interest in tightly held $ZIOP with $XON Kirk's history could cause HUGE run on deal PR...& then reval http://t.co/vnklKntk8T
biotech 2050
24 Oct 14 08:37:05
RT @pharmamaven: $ZIOP option vol & $BMY deal coming in ZIOP space as ZIOP& $XON confirmed partner discussions w/ MANY Big Pharm/Bios http:…
rc
24 Oct 14 08:08:26
$ZIOP option vol & $BMY deal coming in ZIOP space as ZIOP& $XON confirmed partner discussions w/ MANY Big Pharm/Bios http://t.co/LYNIlGTlEA
809trader
24 Oct 14 07:45:48
RT @pharmamaven: 2000+ calls traded Tues&Wed & 9000+ yesterday (vs 50/day avg) & $ZIOP just blew through both 50 DMA & EMA.Kirk/ $XON will …
Me Likeitalot
24 Oct 14 07:44:19
RT @pharmamaven: 2000+ calls traded Tues&Wed & 9000+ yesterday (vs 50/day avg) & $ZIOP just blew through both 50 DMA & EMA.Kirk/ $XON will …
biotech 2050
24 Oct 14 07:42:42
RT @pharmamaven: Respected $300/mo pay service cites high $ZIOP option vol &BMY big immunology announcement coming this month. $XON RJ Kirk…
rc
24 Oct 14 07:42:26
Respected $300/mo pay service cites high $ZIOP option vol &BMY big immunology announcement coming this month. $XON RJ Kirk deal coming? $IBB
Me Likeitalot
24 Oct 14 07:39:04
$XON Wondering when the run back to $25 starts. Overdue.
biotech 2050
24 Oct 14 07:34:37
RT @pharmamaven: 2000+ calls traded Tues&Wed & 9000+ yesterday (vs 50/day avg) & $ZIOP just blew through both 50 DMA & EMA.Kirk/ $XON will …
rc
24 Oct 14 07:31:05
2000+ calls traded Tues&Wed & 9000+ yesterday (vs 50/day avg) & $ZIOP just blew through both 50 DMA & EMA.Kirk/ $XON will get deal done soon
Julian Close
24 Oct 14 06:14:34
Critical Alerts for $INFN, $DAN, $NOW, $XON and $KMX from InvestorsObserver today: http://t.co/NAVBOuvfoU #OptionsTrading #CoveredCalls
Investors Observer
24 Oct 14 06:14:34
Critical Alerts for $INFN, $DAN, $NOW, $XON and $KMX from InvestorsObserver today: http://t.co/ysXJxQrnLr #OptionsTrading #CoveredCalls
Sleek Money
24 Oct 14 04:52:18
Intrexon Corp Upgraded to “Neutral” by Zacks $XON http://t.co/MWCti3JaVS
Gotham City Capital
24 Oct 14 02:20:53
@Biotech2050 $XON what's their powerhouse?? It's amazing that I know absolutely nothing about this company.. After all these years..
biotech 2050
24 Oct 14 02:17:34
@TravisMKnight my portfolio is all set for the long run $celg $gild $npsp $halo $dyax $tgtx $ziop $xon $ptx $crmd no more add ons for now
biotech 2050
24 Oct 14 02:10:02
@TravisMKnight take a look at $halo fundamentals long term plus $xon & $ziop might be upto ...
biotech 2050
23 Oct 14 23:40:57
Is Kirk negotiating a deal for $XON $ZIOP in immuno-onclogy? IV Post by Rob_Cos http://t.co/7zDJkK7Pj9 $BMY $NVS $RHHBY $IBB #biotech $GILD
Sam
23 Oct 14 22:36:59
RT @StockSignaling: Healthcare Sector: Upgrades: $QDEL $GSK $BRKR $NLNK $EXEL $XON $BSX $COO $BIIB $STE $PACB $ALGN $AMRI $ACT $UNH http://…
Who wants to know?
23 Oct 14 22:34:38
RT @StockSignaling: Healthcare Sector: Upgrades: $QDEL $GSK $BRKR $NLNK $EXEL $XON $BSX $COO $BIIB $STE $PACB $ALGN $AMRI $ACT $UNH http://…
Christian
23 Oct 14 22:32:09
RT @StockSignaling: Healthcare Sector: Upgrades: $QDEL $GSK $BRKR $NLNK $EXEL $XON $BSX $COO $BIIB $STE $PACB $ALGN $AMRI $ACT $UNH http://…
Stock Signaling
23 Oct 14 22:31:18
Healthcare Sector: Upgrades: $QDEL $GSK $BRKR $NLNK $EXEL $XON $BSX $COO $BIIB $STE $PACB $ALGN $AMRI $ACT $UNH http://t.co/Vtx6dLy0Nw #spy
equities.com
23 Oct 14 20:34:07
Intrexon (XON) Jumps 11.58% on October 23 $XON http://t.co/5ENROfrMXs
wininstocks2014
23 Oct 14 20:08:31
XON 20.62 Stock Charts $XON Intrexon Corp. (NYSE) Last Updated: 10/23/2014 22:08:31 XON Stock Chart - 1 Month http://t.co/vLXqpvHvZh
wininstocks2014
23 Oct 14 20:06:55
XON 20.62 Stock Charts $XON Intrexon Corp. (NYSE) Last Updated: 10/23/2014 22:06:55 XON Stock Chart - 1 Month http://t.co/61tCigfo3t
biotech 2050
23 Oct 14 14:32:25
RT @pharmamaven: A pay service is citing high $ZIOP option volume says in immune space & BMY going to have big announcement in that area en…
				
				
By  +Follow August 7, 2013 11:03AM
Share:

Comments

 

blog comments powered by Disqus

About us

Equities.com is the most advanced interactive online social ecosystem for the financial industry, serving as a resource center and next-generation communication platform that connects self-directed investors with public issuers, market experts, and professional service providers and vendors. Registered members can leverage our exclusive proprietary research tools such as the Small-Cap Stars, which outperformed 90% of all small-cap mutual funds, and robust do-it-yourself E.V.A. research reports. The Equities.com Issuer Dashboard is the ideal tool to communicate and manage investor awareness campaigns to the investment community, as well as to access valuable resources to help your company grow.

Market Data powered by QuoteMedia.
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Terms of Use.